Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
Record consolidated net revenue of $84.5 million for full-year 2023 Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
Coming Soon: 96th SIBS Congress in Italy
The 96th National Congress will be held in L’Aquila, from 25 to 28 April 2024, at the Palazzo dell’Emiciclo, headquarters of the Regional Council of the Abruzzo Region (in via Michele Iacobucci, 4), as approved by our Board of Directors. The location of the Palazzo dell’Emiciclo is central and strategic, reachable on foot from hotels, B&Bs, and holiday homes in the center. The main monuments and places of interest in L’Aquila are in fact all located in the historic center. The official language of the congress will, as always, be Italian. The scheduled sessions will be in sequence to allow everyone to follow the scientific works. There will be masterly readings with prestigious speakers. If the contributions received do not allow everyone to have space for oral communication, one or more video poster sessions will also be organized. The scientific…
Neues Meniskusgewebe aus dem 3D-Drucker
Gerissene und beschädigte Menisken infolge eines Traumas sind sehr häufige Knieverletzungen, die Schmerzen und Bewegungseinschränkungen verursachen und zu Osteoarthritis führen können. Meniskusverletzungen können eine Operation erfordern, um die Gewebeschäden zu beheben und die Beweglichkeit wiederherzustellen. In einem Artikel, der im Fachblatt Applied Biosciences erschien, wird die biomechanische Prüfung eines 3D-gedruckten Meniskus beschrieben. Insbesondere interessierte die Forschenden, ob der gedruckte Meniskus die Festigkeit und Haltbarkeit besitzt, um Meniskusrisse wirksam zu reparieren und die Biomechanik des Knies wiederherzustellen. Die Publikation will „Schritte aufzeigen, die erforderlich sind, um neuartige Meniskusreparaturvorrichtungen zu testen, bevor man zu Tierversuchen übergeht“. Im ersten Testschritt wurde die Fähigkeit des 3D-gedruckten Meniskus ermittelt, der chirurgischen Fixierung standzuhalten, indem die Ausziehkraft der Naht gemessen wurde. Die Autoren zeigen, dass vertikale 2/0-Seiden- oder Fiberwire-Nähte durchschnittlich 1,4 bzw. 1,8 N benötigen, um durch den Meniskus zu ziehen, während horizontale Nähte nur 0,7…
Must Read: The Integration of Artificial Intelligence into Clinical Practice
A research article in Applied Biosciences provides a fundamental synopsis of current research pertaining to artificial intelligence (AI) within the domain of clinical practice. Artificial intelligence has revolutionized the field of medicine and healthcare by providing innovative solutions to complex problems. One of the most important benefits of AI in clinical practice is its ability to investigate extensive volumes of data with efficiency and precision. This has led to the development of various applications that have improved patient outcomes and reduced the workload of healthcare professionals. AI can support doctors in making more accurate diagnoses and developing personalized treatment plans. Successful examples of AI applications are outlined for a series of medical specialties like cardiology, surgery, gastroenterology, pneumology, nephrology, urology, dermatology, orthopedics, neurology, gynecology, ophthalmology, pediatrics, hematology, and critically ill patients, as well as diagnostic methods. Special reference is made…
Fisher Z is back
Hautnah am Zeitgeist, an den wichtigen Themen des politischen Weltgeschehens, interessiert an den Geschichten seiner erdachten, aber realen Protagonisten – das ist das musikalische Triptychon, das Fischer-Z schon seit jeher ausmachen, und das auch wieder auf dem neuen Album „Triptych“ und im Frühjahr 2024 live auf der Bühne präsentiert wird. Die Band, im Vergleich zur Debüt-LP „Word Salad“ (1979) auf drei Positionen umbesetzt und mit einer Gitarre mehr auf der Bühne, begeistert in ihren Live-Auftritten nach wie vor. Fischer-Z ist mit Hits wie „Marliese“ oder „So Long“ eine der Ikonen des New Wave und des White Reggae – Fischer-Z steht hier ebenbürtig neben The Police und Madness.
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
CUPERTINO, Calif., March 28, 2024 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at the 2024 Schizophrenia International Research Society (SIRS) Annual Meeting, to be held April 3-7, 2024, in Florence, Italy. Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
Arcutis today announced that Arcutis management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024. Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
CHAPEL HILL, N.C., March 28, 2024 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced full year 2023 financial results, and provided clinical development and business updates. Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
